ORG 2766

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597752

CAS#: 50913-82-1

Description: ORG 2766 is an ACTH 4-9 (H-Met(O)-Glu-His-Phe-D-Lys-Phe-OH) analog and neurotrophic peptide.


Chemical Structure

img
ORG 2766
CAS# 50913-82-1

Theoretical Analysis

MedKoo Cat#: 597752
Name: ORG 2766
CAS#: 50913-82-1
Chemical Formula: C34H51N9O11S
Exact Mass: 793.34
Molecular Weight: 793.890
Elemental Analysis: C, 51.44; H, 6.48; N, 15.88; O, 22.17; S, 4.04

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ORG 2766; ORG-2766; ORG2766;

IUPAC/Chemical Name: (7S,10R,13S,16S,19S)-16-((1H-imidazol-4-yl)methyl)-3,19-diamino-10-(4-aminobutyl)-13-benzyl-7-methyl-21-(methylsulfonyl)-4,6,9,12,15,18-hexaoxo-5-oxa-8,11,14,17-tetraazadocosan-22-oic acid

InChi Key: LQQVCQXRTNSBLF-HGLQDSPTSA-N

InChi Code: InChI=1S/C34H51N9O11S/c1-4-22(36)34(51)54-33(50)19(2)40-29(45)24(12-8-9-13-35)41-30(46)25(14-20-10-6-5-7-11-20)43-31(47)26(15-21-17-38-18-39-21)42-28(44)23(37)16-27(32(48)49)55(3,52)53/h5-7,10-11,17-19,22-27H,4,8-9,12-16,35-37H2,1-3H3,(H,38,39)(H,40,45)(H,41,46)(H,42,44)(H,43,47)(H,48,49)/t19-,22?,23-,24+,25-,26-,27?/m0/s1

SMILES Code: C[C@@H](C(OC(C(N)CC)=O)=O)NC([C@@H](CCCCN)NC([C@H](CC1=CC=CC=C1)NC([C@H](CC2=CNC=N2)NC([C@H](CC(S(=O)(C)=O)C(O)=O)N)=O)=O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 793.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Van der Zee CE, Brakkee JH, Gispen WH. alpha-MSH and Org.2766 in peripheral nerve regeneration: different routes of delivery. Eur J Pharmacol. 1988 Mar 15;147(3):351-7. PubMed PMID: 2837394.

2: Valk GD, Kappelle AC, Tjon-A-Tsien AM, Bravenboer B, Bakker K, Michels RP, Groenhout CM, Bertelsmann FW. Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766. J Neurol. 1996 Mar;243(3):257-63. PubMed PMID: 8936356.

3: Buitelaar JK, Dekker ME, van Ree JM, van Engeland H. A controlled trial with ORG 2766, an ACTH-(4-9) analog, in 50 relatively able children with autism. Eur Neuropsychopharmacol. 1996 Mar;6(1):13-9. PubMed PMID: 8866933.

4: Hovestadt A, van der Burg ME, Verbiest HB, van Putten WL, Vecht CJ. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol. 1992 Mar;239(3):143-6. PubMed PMID: 1315383.

5: Buitelaar JK, van Engeland H, de Kogel KH, de Vries H, van Hooff JA, van Ree JM. The use of adrenocorticotrophic hormone (4-9) analog ORG 2766 in autistic children: effects on the organization of behavior. Biol Psychiatry. 1992 Jun 1;31(11):1119-29. PubMed PMID: 1326339.

6: Sporel-Ozakat RE, Edwards PM, Van der Hoop RG, Gispen WH. An ACTH-(4-9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats. Eur J Pharmacol. 1990 Sep 21;186(2-3):181-7. PubMed PMID: 1963145.

7: van Huizen F, Philipsen HL, Draaijer J, Hermkens PH, ten Kortenaar PB, Tonnaer JA. Binding of a biotinylated neurotrophic ACTH(4-9) analogue, Org 2766, to neurofilament-positive cells in primary or cell line cultures. Peptides. 1993 Nov-Dec;14(6):1205-13. PubMed PMID: 8134302.

8: Cardinaal RM, de Groot JC, Huizing EH, Veldman JE, Smoorenburg GF. Histological effects of co-administration of an ACTH((4-9)) analogue, ORG 2766, on cisplatin ototoxicity in the albino guinea pig. Hear Res. 2000 Jun;144(1-2):157-67. PubMed PMID: 10831874.

9: Fekete M, De Wied D. Naltrexone-insensitive facilitation and naltrexone-sensitive inhibition of passive avoidance behavior of the ACTH-(4-9) analog (ORG 2766) are located in two different parts of the molecule. Eur J Pharmacol. 1982 Jul 16;81(3):441-8. PubMed PMID: 6288413.

10: Van der Zee CE, Van der Hoop RG, Gispen WH. Beneficial effect of Org 2766 in treatment of peripheral neuropathy in streptozocin-induced diabetic rats. Diabetes. 1989 Feb;38(2):225-30. PubMed PMID: 2536628.

11: Partanen JV, Soininen H, Riekkinen PJ. Does an ACTH derivative (Org 2766) prevent deterioration of EEG in Alzheimer's disease? Electroencephalogr Clin Neurophysiol. 1986 Jun;63(6):547-51. PubMed PMID: 2422004.

12: Fekete M, Drago F, Van Ree JM, Bohus B, Wiegant VM, De Wied D. Naltrexone-sensitive behavioral actions of the ACTH 4-9 analog (Org 2766). Life Sci. 1983 May 9;32(19):2193-204. PubMed PMID: 6302425.

13: Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol. 1997 Nov;67(2):172-7. PubMed PMID: 9367703.

14: Hamers FP, Pette C, Neijt JP, Gispen WH. The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats. Eur J Pharmacol. 1993 Mar 16;233(1):177-8. PubMed PMID: 8097161.

15: Plantinga LC, Verhaagen J, Wong SL, Edwards PM, Bär PR, Gispen WH. The neurotrophic peptide Org 2766 does not influence the expression of the immediate early gene c-fos following sciatic nerve crush in the rat. Int J Dev Neurosci. 1994 Apr;12(2):117-25. PubMed PMID: 7942087.

16: Murry R, McLane JA, Gruener G. Effects of ORG 2766, a neurotrophic ACTH4-9 analogue, in neuroblastoma cells. Ann N Y Acad Sci. 1993 May 28;679:270-5. PubMed PMID: 8390145.

17: Müller LJ, Gerritsen van der Hoop R, Moorer-van Delft CM, Gispen WH, Roubos EW. Morphological and electrophysiological study of the effects of cisplatin and ORG.2766 on rat spinal ganglion neurons. Cancer Res. 1990 Apr 15;50(8):2437-42. PubMed PMID: 2156619.

18: Buitelaar JK, van Engeland H, de Kogel K, de Vries H, van Hooff J, van Ree J. The adrenocorticotrophic hormone (4-9) analog ORG 2766 benefits autistic children: report on a second controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 1992 Nov;31(6):1149-56. PubMed PMID: 1331023.

19: Walker JM, Berntson GG, Sandman CA, Kastin AJ, Akil H. Induction of analgesia by central administration of ORG 2766, an analog of ACTH4--9. Eur J Pharmacol. 1981 Jan 5;69(1):71-9. PubMed PMID: 6258942.

20: Schmidt MS, Chirino-Barcelo FI, McDaniel WF. ORG 2766 fails to improve visual functions in rats with occipital lesions. Neuroreport. 1992 Jan;3(1):29-32. PubMed PMID: 1319226.